Steep tariffs could make medicines like these prohibitively expensive or even physically impossible to obtain.
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea.
While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as high as 250%.
Either way, the swift result would be empty shelves at pharmacies nationwide.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
Sally C. Pipes
Steep tariffs could make medicines like these prohibitively expensive or even physically impossible to obtain.
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea.
While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as high as 250%.
Either way, the swift result would be empty shelves at pharmacies nationwide.
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.